Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
1 other identifier
observational
1,000
1 country
1
Brief Summary
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS). Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA. These 5 cohorts will be subject to standardized clinical monitoring.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 11, 2013
CompletedFirst Submitted
Initial submission to the registry
April 25, 2019
CompletedFirst Posted
Study publicly available on registry
June 3, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 31, 2028
June 3, 2025
May 1, 2025
14.6 years
April 25, 2019
May 22, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Remission rate or absence of synovitis in Rheumatoid arthritis patients
Through the entire study, during approximately 15 years
Other Outcomes (3)
Remission rates improvement in Juvenile arthritis (JIA) patients
Through the entire study, during approximately 15 years
Reduction in damage rate in Systemic Lupus Erythematosus patients
Through the entire study, during approximately 15 years
Inclusion of at least 80% of the incident cases of diffuse Systemic sclerosis
Through the entire study, during approximately 15 years
Study Arms (5)
juvenile idiopathic arthritis (JIA)
aged \<= 16 y.o. recent diagnosis of JIA and DMARDs treatment-naive patients; aged \<18 y.o. recent diagnosis of JIA
rheumatoid arthritis (RA)
aged =\>18; =\< 50 y.o. recent diagnosis of RA and DMARDs treatment-naive patients
diffuse systemic sclerosis (dSS)
aged =\>18; =\< 50 y.o. recent diagnosis of dSS and DMARDs treatment-naive patients
seronegative arthritis (UA)
aged =\>18; =\< 50 y.o. recent diagnosis of UA and DMARDs treatment-naive patients
systemic lupus erythematosus (SLE)
aged =\>18; =\< 50 y.o. recent diagnosis of SLE and DMARDs treatment-naive patients
Eligibility Criteria
Patients with juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis
You may qualify if:
- Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).
- Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
You may not qualify if:
- Treated for \> 3 months
- \> 50 years old
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UCLouvain
Brussels, 1200, Belgium
Biospecimen
residual blood and urine sampling
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Patrick Durez, Pr
UCLouvain - IREC
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2019
First Posted
June 3, 2025
Study Start
September 11, 2013
Primary Completion (Estimated)
March 31, 2028
Study Completion (Estimated)
March 31, 2028
Last Updated
June 3, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share